Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Medication eases obsessive-compulsive symptoms

01.08.2005


A medication used to ease symptoms of amyotrophic lateral sclerosis, or Lou Gehrig’s disease, also is helpful in treating people with treatment-resistant obsessive-compulsive disorder (OCD), according to a pilot study at Yale School of Medicine.



Although the study included only 13 patients, the preliminary results are promising for persons who have found no relief using other medications and cognitive behavioral therapy, said the first author, Vladimir Coric, M.D., assistant clinical professor in the Department of Psychiatry and director of the Yale OCD clinic.

"Riluzole appears to have significant antiobsessional, antidepressant, and antianxiety properties," said Coric, who will be presenting the data Friday at the Obsessive-Compulsive Foundation annual conference in San Diego.


OCD currently is treated with serotonin reuptake inhibitors, cognitive behavioral therapy and dopamine antagonists, which reduce symptoms in 40-60 percent of patients. "However, a number of patients remain dramatically symptomatic even with the combination of pharmacotherapy and cognitive behavioral therapy," Coric said.

OCD symptoms include obsessive checking, cleaning, washing, counting, hoarding, touching, tapping, ordering, arranging, rubbing, and other repetitive behaviors. Coric said treatment-resistant OCD is one of the few psychiatric indications for neurosurgical intervention. "Novel therapeutic strategies are urgently needed," he said.

Since recent neuroimaging studies suggest that individuals with OCD have abnormalities in corticostriatal glutamate function, Coric and his colleagues tested riluzole, a glutamate modulating agent, on patients with OCD. Glutamate is the most abundant excitatory neurotransmitter in the brain, but when in excess may cause neurotoxicity. Seven of the patients treated with riluzole experienced a 35 percent reduction in symptoms and five were categorized as responsive to the treatment. One patient left the study.

"The use of glutamate modulating agents, such as riluzole, may represent a novel treatment intervention for certain anxiety and mood disorders," Coric said.

Jacqueline Weaver | EurekAlert!
Further information:
http://www.yale.edu

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>